Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
21 | DE file number | DAKZ | 60 2014 087 580.7 |
96 | EP file number | EAKZ | 20 20 4866.6 |
97 | EP publication number | EPN | 3889173 |
54 | Designation/title | TI | OPTIMIERTES FAKTOR-VIII-GEN |
51 | IPC main class | ICM (ICMV) | C07K 14/755 (2006.01) |
22 | DE application date | DAT | Feb 14, 2014 |
96 | EP application date | EAT | Feb 14, 2014 |
43 | Date of first publication | OT | Oct 6, 2021 |
| Date of publication of grant | PET | Jul 5, 2023 |
71/73 | Applicant/owner | INH | Bioverativ Therapeutics Inc., Waltham, MA, US |
72 | Inventor | IN | TAN, Siyuan, Lexington, MA 02421, US; PETERS, Robert, T., Needham, MA 02492, US |
| Address for service | | RWS Group, Translation Division, CHALFONT ST PETER, Bucks SL9 9FG, GB |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 201361765626 P Feb 15, 2013
|
| Due date | FT FG | Feb 28, 2026 Annual fee for the 13th year
Patent fees |
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000003889173A1 Searchable text:
EP000003889173A1 Original document:
EP000003889173B1 Searchable text:
EP000003889173B1 |
43 | Date of first publication | EVT | Oct 6, 2021 |
| Date of the first transfer into DPMAregister | EREGT | Oct 6, 2021 |
| Date of the (most recent) update in DPMAregister | REGT | Jan 3, 2025 (Show all update days)(Hide all update days)- Jan 3, 2025
- Oct 17, 2024
- St.36: changed (technical change)
- Jun 27, 2024; May 23, 2024; Jan 10, 2024; Oct 7, 2023; Jul 27, 2023; Jun 20, 2023; Jun 17, 2023; Jun 15, 2023
- Historical data not available for this/these date(s)
- Oct 6, 2021
- Date of the first transfer into DPMAregister
|